▶ 調査レポート

心臓バイオマーカーの世界市場:マーカーのタイプ別(クレアチンキナーゼ、トロポニン(T、I)、ミオグロビン、ナトリウム利尿ペプチド(BNPおよびNT-ProBNP)、虚血修飾アルブミン、その他)、用途別(心筋梗塞、うっ血性心不全、急性冠症候群、アテローム性動脈硬化症、その他)、検査場所別、地域別分析

• 英文タイトル:Global Cardiac Biomarkers Market - Segmented by Type Of Marker, Application, Location Of Testing and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。心臓バイオマーカーの世界市場:マーカーのタイプ別(クレアチンキナーゼ、トロポニン(T、I)、ミオグロビン、ナトリウム利尿ペプチド(BNPおよびNT-ProBNP)、虚血修飾アルブミン、その他)、用途別(心筋梗塞、うっ血性心不全、急性冠症候群、アテローム性動脈硬化症、その他)、検査場所別、地域別分析 / Global Cardiac Biomarkers Market - Segmented by Type Of Marker, Application, Location Of Testing and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08109資料のイメージです。• レポートコード:B-MOR-08109
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、心臓バイオマーカーの世界市場について調べ、心臓バイオマーカーの世界規模、市場動向、市場環境、マーカーのタイプ別(クレアチンキナーゼ、トロポニン(T、I)、ミオグロビン、ナトリウム利尿ペプチド(BNPおよびNT-ProBNP)、虚血修飾アルブミン、その他)分析、用途別(心筋梗塞、うっ血性心不全、急性冠症候群、アテローム性動脈硬化症、その他)分析、検査場所別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・心臓バイオマーカーの世界市場インサイト
・心臓バイオマーカーの世界市場環境
・心臓バイオマーカーの世界市場動向
・心臓バイオマーカーの世界市場規模
・心臓バイオマーカーの世界市場規模:マーカーのタイプ別(クレアチンキナーゼ、トロポニン(T、I)、ミオグロビン、ナトリウム利尿ペプチド(BNPおよびNT-ProBNP)、虚血修飾アルブミン、その他)
・心臓バイオマーカーの世界市場規模:用途別(心筋梗塞、うっ血性心不全、急性冠症候群、アテローム性動脈硬化症、その他)
・心臓バイオマーカーの世界市場規模:検査場所別
・心臓バイオマーカーの世界市場:地域別市場規模・分析
・心臓バイオマーカーの北米市場規模・予測
・心臓バイオマーカーのアメリカ市場規模・予測
・心臓バイオマーカーのヨーロッパ市場規模・予測
・心臓バイオマーカーのアジア市場規模・予測
・心臓バイオマーカーの日本市場規模・予測
・心臓バイオマーカーの中国市場規模・予測
・心臓バイオマーカーのインド市場規模・予測
・心臓バイオマーカーの韓国市場規模・予測
・関連企業情報・競争状況

The cardiac biomarkers market is expected to register a CAGR of about 18.5%, during the forecast period. Biomarkers have an essential role in the diagnosis, management, risk stratification, and clinical decision-making in the patients suffering from disease. Cardiac biomarkers are measurable and quantifiable biological parameters, which are detected in the blood and serve as indices for physiological and pathological assessment by a specialized immunoassay.

Increasing Prevalence of Cardiovascular Diseases

Myocardial infarction is caused is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. Timely diagnosis of heart conditions allow clinicians to analyze the risk of their patients and prescribe relevant treatment. Biomarkers enable us for timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. Increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements using cardiac will drive the market in the forecasted period.

Stringent Regulation

After the identification of a biomarker data from the discovery tools indicate that it may answer the clinical question posed, its successful translation will require an assay that must meet stringent requirements. This step represents a critical cause of failure for biomarkers, as the development of a robust and reproducible assay, with appropriate sensitivity, specificity, and precision, depends on a standards-based discovery process. For assays to be submitted for FDA qualification or clinical validation the test must be analytically validated and, depending on the targeted clinical application, evaluated in one or more clinical trials. Finally, as the assay moves to later discovery, it is important to define how clinical decision making will be impacted by the assay, and increasingly careful considerations to the economics of manufacturing, competing technologies, and scale must also be considered. All these steps require a lot of time and slow down the overall development process. Other factors, such as poor reimbursement policies will restrain the market growth.

Geographical or Segment Scenario

North America is projected to lead the global market, as there is a high demand for testing due to high rate of CVD prevalence and growing awareness towards application cardiac biomarkers in cardiac diagnostics. Asia-Pacific is estimated to register the fastest CAGR owing to the increasing disposable incomes, affordable solutions, and increased funding in R&D in the field advanced cardiac treatments.

Key Developments in the Market

• January 2017 – Roche announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack

Major players – ALERE INC., BECKMAN COULTER, BECTON, DICKINSON AND CO., BIOMERIEUX, BIO-RAD LABORATORIES, RANDOX LABORATORIES, ROCHE DIAGNOSTICS CORPORATION, SIEMENS HEALTHCARE AND THERMO FISHER SCIENTIFIC, amongst others.

Reasons to Purchase this Report

• Current and future cardiac biomarkers market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Prevalence Of Cardiovascular Diseases
6.1.2 Technological Advancements Using Cardiac Biomarkers
6.1.3 Growing Funding From Public and Private Organizations for R&D
6.2 Market Restraints
6.2.1 Stringent Regulation
6.2.2 Poor Reimbursement Policies
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type Of Marker
7.1.1 Creatine Kinase
7.1.2 Troponins (T,I)
7.1.3 Myoglobin
7.1.4 Natriuretic Peptides (BNP And NT-ProBNP)
7.1.5 Ischemia Modified Albumin
7.1.6 Others
7.2 By Application
7.2.1 Myocardial Infarction
7.2.2 Congestive Heart Failure
7.2.3 Acute Coronary Syndrome
7.2.4 Atherosclerosis
7.2.5 Others
7.3 By Location Of Testing
7.3.1 Point of Care Testing
7.3.2 Laboratory Testing
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 ABBOTT LABORATORIES
9.2 Alere Inc.
9.3 Beckman Coulter
9.4 Becton, Dickinson And Co.
9.5 Biomerieux
9.6 Bio-Rad Laboratories
9.7 Randox Laboratories
9.8 Roche Diagnostics Corporation
9.9 Siemens Healthcare
9.10 Thermo Fisher Scientific
9.11 List Not Exhaustive
10. Future of the Market